Prostate Cancer Therapy Zytiga Makes WHO’s Essential Medicines List

Prostate Cancer Therapy Zytiga Makes WHO’s Essential Medicines List
Zytiga (abiraterone acetate), a kind of hormone therapy, has been added to the World Health Organization’s (WHO) Essential Medicines List for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Updated every two years since 1977, the publication focuses on recommendations for malignancies such as prostate cancer and other diseases, and is used by 150 countries to help develop their own local lists of essential medicine. It helps those countries prioritize affordable and widely available treatments and diagnostic tests. The list adds 28 medicines for adults and 23 for children, and specifies new uses for 26 already-listed products. In all, 460 products are deemed essential for addressing key public health needs. Also updated was the List of Essential Diagnostics. “While several new cancer treatments have been marketed in recent years, only a few deliver sufficient therapeutic benefits to be essential,” WHO said in a
Subscribe or to access all post and page content.